Open AccessGenetic reduction of mTOR extends lifespan in a mouse model of Hutchinson‐Gilford Progeria syndrome
Author(s) -
Cabral Wayne A.,
Tavarez Urraca L.,
Beeram Indeevar,
Yeritsyan Diana,
Boku Yoseph D.,
Eckhaus Michael A.,
Nazarian Ara,
Erdos Michael R.,
Collins Francis S.
Publication year - 2021
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/acel.13457
Subject(s) - lmna , progeria , biology , lamin , premature aging , genetics , phenotype , mutation , cancer research , gene
Hutchinson‐Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder most notably characterized by cardiovascular disease and premature death from myocardial infarction or stroke. The majority of cases are caused by a de novo single nucleotide mutation in the LMNA gene that activates a cryptic splice donor site, resulting in production of a toxic form of lamin A with a 50 amino acid internal deletion, termed progerin. We previously reported the generation of a transgenic murine model of progeria carrying a human BAC harboring the common mutation, G608G, which in the single‐copy state develops features of HGPS that are limited to the vascular system. Here, we report the phenotype of mice bred to carry two copies of the BAC, which more completely recapitulate the phenotypic features of HGPS in skin, adipose, skeletal, and vascular tissues. We further show that genetic reduction of the mechanistic target of rapamycin (mTOR) significantly extends lifespan in these mice, providing a rationale for pharmacologic inhibition of the mTOR pathway in the treatment of HGPS.